Effect of Plant-based Diets on Liver Biomarkers, Cardiometabolic Health, and Exposure to Environmental Contaminants and Endocrine Disruptors in Patients With Metabolic Liver Disease.
NCT07503431 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2026-04-06
Summary
Plant-based diets have gained increasing recognition for their sustainability and their benefits on cardiometabolic and liver health. However, evidence regarding their effects in patients with metabolic liver disease (MetLD) remains limited. The primary objective of this project is to compare the effects of a traditional Mediterranean diet and a Mediterranean diet exclusively based on plant-derived foods on liver parameters, cardiometabolic health, gut microbiota, and exposure to environmental contaminants in patients with MetLD.
This study is a randomized clinical trial with a 1:1 allocation ratio into two groups: a traditional Mediterranean diet, considered the standard diet in our setting and recommended for this condition, and a Mediterranean diet exclusively based on plant-derived foods, both designed by registered dietitians. The intervention will last 12 weeks.
Anthropometric, metabolic, hepatic, inflammatory, and quality of life variables will be assessed. Additionally, gut microbiota, genetic variants associated with MetLD, and internal exposure to environmental contaminants will be evaluated using biological samples. A 4-week follow-up after the intervention will also be conducted to assess the integration of lifestyle recommendations among participants.
The results will contribute to the development of safe, sustainable, and cost-effective nutritional strategies and may serve as a basis for future clinical guidelines integrating precision nutrition and planetary health in the management of chronic liver diseases.
The traditional Mediterranean diet has shown metabolic and hepatic benefits; however, its reformulation toward a predominantly plant-based pattern may enhance these effects by reducing saturated fat intake and increasing the consumption of fiber, bioactive compounds, and fatty acids with a more favorable profile. Moreover, this type of diet limits the intake of animal-based foods associated with the bioaccumulation of environmental contaminants such as PFAS and heavy metals, which are increasingly implicated in the progression of MetLD.
This project hypothesizes that a Mediterranean diet based exclusively on plant-derived foods, compared to a traditional Mediterranean diet, will lead to greater improvements in hepatic, metabolic, and inflammatory parameters in patients with MetLD, and will additionally be associated with a lower internal burden of bioaccumulative environmental contaminants.
Primary objective To evaluate the effect of a Mediterranean diet based exclusively on plant-derived foods on MetLD, assessed non-invasively through biochemical and elastographic parameters.
Secondary objectives To evaluate changes in metabolic parameters, anthropometric measures, and body composition.
To examine changes in systemic inflammatory markers, such as C-reactive protein and the neutrophil-to-lymphocyte ratio.
To assess exposure to environmental contaminants, specifically heavy metals (lead, cadmium, mercury) and endocrine disruptors such as perfluorinated compounds (PFAS), and their relationship with liver damage.
To evaluate whether genetic variants associated with susceptibility to and progression of MetLD modulate hepatic and metabolic responses to dietary patterns.
To analyze changes in gut microbiota following the plant-based diet and their association with liver improvement.
Conditions
- Metabolic Dysfunction-associated Liver Disease
Interventions
- OTHER
-
Traditional Mediterranean diet
This dietary pattern is considered the standard of care in the study setting and includes a balanced intake of plant- and animal-derived foods, consistent with current clinical recommendations for metabolic liver disease. The diet emphasizes high consumption of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil as the primary source of fat. Moderate intake of fish, poultry, eggs, and low-fat dairy products will be encouraged, while red and processed meats, added sugars, and ultra-processed foods will be limited.
- OTHER
-
Vegan Mediterranean diet
This dietary pattern is designed and supervised by registered dietitians and emphasizes high consumption of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil as the primary source of fat, in line with Mediterranean dietary principles. All animal-derived foods (including meat, fish, seafood, dairy products, and eggs) will be excluded. Legumes, whole grains, nuts, and seeds will serve as the main sources of protein and healthy fats. Participants will be encouraged to prioritize whole, minimally processed foods; however, plant-based alternatives to meat and dairy may be allowed in cases where necessary to support adherence.
Sponsors & Collaborators
-
IMDEA Food
collaborator OTHER -
Hospital Clinico Universitario San Cecilio
collaborator OTHER -
Hospital Universitario Puerta del Hierro
collaborator UNKNOWN -
Miguel López Moreno
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-18
- Primary Completion
- 2026-12-19
- Completion
- 2027-03-10
Countries
- Spain
Study Locations
More Related Trials
-
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
NCT06394206 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
NCT06773221 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
NCT02051842 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
NCT07194863 ·Status: NOT_YET_RECRUITING
-
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NCT07313007 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
NCT06078722 ·Status: UNKNOWN
-
Probiotics in the Treatment of NAFLD
NCT02764047 ·Status: UNKNOWN ·Phase: NA
-
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
NCT02400216 ·Status: COMPLETED
-
Manual Therapy in Metabolic Liver Disease
NCT06338618 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
NCT07021443 ·Status: COMPLETED
-
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT02030977 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
NCT06750276 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Synbiotic Treatment in NAFLD
NCT01680640 ·Status: COMPLETED ·Phase: NA
-
Study on Risk Factors and Prognosis of MASLD
NCT07433205 ·Status: COMPLETED
-
Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH
NCT05357248 ·Status: COMPLETED ·Phase: NA
-
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
NCT01963845 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease
NCT05107271 ·Status: COMPLETED
-
Integrated Approaches for Identifying Molecular Targets in Liver Disease
NCT03915002 ·Status: COMPLETED
-
A Hepatitis B With Hepatic Steatosis Study
NCT02392598 ·Status: UNKNOWN
-
Faecal Microbiota Transplantation for Liver Cirrhosis
NCT04932577 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04465032 ·Status: UNKNOWN ·Phase: PHASE4
-
Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study
NCT07188220 ·Status: RECRUITING
-
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
NCT02508623 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486 ·Status: NOT_YET_RECRUITING